Does Tigecycline Work Against MRSA?
Tigecycline has in vitro activity against MRSA, with MIC90 values typically 1-2 mg/L, indicating susceptibility for most strains.[1][2] It inhibits bacterial protein synthesis by binding the 30S ribosomal subunit, bypassing common MRSA resistance mechanisms like mecA gene alterations in penicillin-binding proteins.[3]
How Effective Is Tigecycline Compared to Standard MRSA Treatments?
For skin and soft tissue infections (SSTIs), tigecycline matches vancomycin's clinical success rates (around 85-90% cure), but meta-analyses show no superiority and higher failure in severe cases.[4][5] In complicated intra-abdominal infections with MRSA, tigecycline performs similarly to imipenem but with more gastrointestinal side effects.[6]
| Antibiotic | MRSA Coverage | Cure Rate in SSTIs (vs. vancomycin) | Key Trials |
|------------|---------------|-------------------------------------|------------|
| Tigecycline | Good (MIC ≤2 mg/L) | Equivalent (~86%)[4] | FOCUS 1/2 trials |
| Vancomycin | Gold standard | Reference (~90%)[4] | - |
| Daptomycin | Excellent | Superior in bacteremia (44% vs. 23%)[7] | Bacteremia CAPTURE |
| Linezolid | Excellent | Equivalent or better in pneumonia[8] | ZEPHyR trial |
Tigecycline underperforms in bacteremia and pneumonia due to sub-MIC concentrations in lungs and serum.[9]
When Is Tigecycline Chosen Over Vancomycin or Daptomycin?
Clinicians reserve tigecycline for polymicrobial infections or vancomycin-resistant strains, as FDA warnings highlight higher mortality in VABP (ventilator-associated bacterial pneumonia; 17.9% vs. 12.5% for comparators).[10] It's not first-line for MRSA per IDSA guidelines, which prioritize vancomycin, daptomycin, or linezolid.[11]
What Are the Main Drawbacks and Side Effects?
Tigecycline causes more nausea (26%) and vomiting (18%) than vancomycin (10-15%).[4] It requires twice-daily IV dosing with a loading dose, and black-box warnings cover mortality risk and lack of efficacy in bacteremia.[10] Resistance emerges faster in high-inoculum infections due to its bacteriostatic action.[12]
Alternatives for Multidrug-Resistant MRSA
For VRE or polymyxin-resistant cases, tigecycline pairs with others, but ceftaroline (MIC90 1 mg/L) or dalbavancin offer better tissue penetration.[13] Tedizolid edges linezolid in skin infections with fewer adverse events.[14]
[1] DrugPatentWatch.com
[2] Clinical Infectious Diseases, 2005;40:1737-1742
[3] Antimicrobial Agents and Chemotherapy, 2004;48:1720-1726
[4] Journal of Antimicrobial Chemotherapy, 2010;65:2403-2414
[5] FDA Label, Tygacil (tigecycline)
[6] New England Journal of Medicine, 2005;353:2583-2594
[7] Clinical Infectious Diseases, 2011;53:338-345
[8] Lancet Infectious Diseases, 2012;12:281-289
[9] Pharmacotherapy, 2009;29:259-273
[10] FDA Safety Communication, 2013
[11] Clinical Infectious Diseases, 2011;52:e18-e55
[12] Antimicrobial Agents and Chemotherapy, 2009;53:2636-2640
[13] Journal of Antimicrobial Chemotherapy, 2014;69:823-831
[14] Journal of Antimicrobial Chemotherapy, 2015;70:1884-1891